Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2–negative advanced breast cancer from the United States, Europe, and Israel

BACKGROUND: In clinical trials, poly (ADP-ribose) polymerase inhibitors (PARPi) versus chemotherapy resulted in significantly improved progression-free survival, manageable adverse event profiles, and favorable patient-reported outcomes (PROs) in patients with human epidermal growth factor receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahtani, Reshma, Niyazov, Alexander, Arondekar, Bhakti, Lewis, Katie, Rider, Alex, Massey, Lucy, Lux, Michael Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773591/
https://www.ncbi.nlm.nih.gov/pubmed/36550413
http://dx.doi.org/10.1186/s12885-022-10325-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773591/
https://www.ncbi.nlm.nih.gov/pubmed/36550413
http://dx.doi.org/10.1186/s12885-022-10325-9

Ejemplares similares